Peptides

PT-141 (Bremelanotide)

Evidence: strong_human

Mechanism of Action

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Dosing Protocol

Standard: Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Maintenance: Research indicates use as-needed, not more than once per 24 hours and no more than 8 doses per month.

Administration: subcutaneousintranasal

Timing: 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Duration: As-needed basis. Not intended for daily use.

Notes

PT-141 is FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women — one of the few peptides with full FDA approval. Nausea is the dose-limiting side effect (40% incidence in trials). Starting at 1 mg and titrating up can mitigate nausea. Works in both men and women through central CNS mechanisms. Effects can persist 24-72 hours. Antiemetic pretreatment (ondansetron 4mg) 30 minutes before PT-141 effectively manages nausea in most clients.

Stacking

  • Kisspeptin-10
  • Melanotan II

Interactions

  • Antihypertensives [MEDIUM] — PT-141 may cause transient blood pressure increase; monitor in hypertensive patients.
  • PDE5 inhibitors (sildenafil, tadalafil) [LOW] — Complementary mechanisms — PT-141 for desire, PDE5i for mechanics. Generally safe to combine.
  • Naltrexone [MEDIUM] — May reduce PT-141 efficacy through opioid system interactions.

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Use of other melanocortin agonists concurrently

Side Effects

  • Nausea (most common, dose-dependent)
  • Flushing
  • Headache
  • Nasal congestion (intranasal route)
  • Transient blood pressure increase
  • Skin darkening with repeated use

Key Papers

  • 10.1111/j.1743-6109.2005.00089.x
  • 10.1007/s11930-020-00293-1

Source Quality

Pharmaceutical-grade (FDA-approved as Vyleesi for HSDD in premenopausal women). Also available through compounding pharmacies.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should PT-141 (Bremelanotide) Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds